Login to Your Account



Financings Roundup

A Blueprint for Success: Third Rock Funds $40M Series A

By Catherine Shaffer


Tuesday, April 12, 2011
Third Rock Ventures has funded its largest ever Series A for new start-up Blueprint Medicines, based in Cambridge, Mass. Blueprint was established to develop cancer therapies based on the company's Insights-to-Validation platform and its chemical library. Blueprint's approach is to use cancer genome data to create kinase-targeted cancer therapies using a personalized medicine approach.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription